Cargando…
Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021
Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit–risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a stud...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859400/ https://www.ncbi.nlm.nih.gov/pubmed/36674204 http://dx.doi.org/10.3390/ijerph20021448 |
_version_ | 1784874345735127040 |
---|---|
author | Azzoug, Chana Nuémi, Gilles Menu, Didier De Maistre, Emmanuel Boulin, Mathieu Putot, Alain Manckoundia, Patrick |
author_facet | Azzoug, Chana Nuémi, Gilles Menu, Didier De Maistre, Emmanuel Boulin, Mathieu Putot, Alain Manckoundia, Patrick |
author_sort | Azzoug, Chana |
collection | PubMed |
description | Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit–risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a study in 2017, we observed that older adults did not seem to receive the same modalities of oral anticoagulants as younger individuals for various reasons. To assess anticoagulation prescribing practices over time, we repeated this cross-sectional study by comparing very old individuals taking DOAC to those taking VKA. Ambulatory individuals aged 80 years and older were included. They were affiliated with the Mutualité Sociale Agricole of Burgundy and were refunded for a medical prescription of oral anticoagulation in March 2021. The demographic characteristics, registered chronic diseases (RCD), number and types of prescribed drugs, and mortality of the DOAC group and the VKA group were compared. A total of 4275 subjects were included in the study: 67.44% (2883) received DOAC and 32.56% (1392) received VKA. The two groups were similar in age. In the DOAC group, there were more women (54.98% vs. 46.98%) (p < 0.001), fewer RCD (91.47% vs. 93.68%) (p = 0.014), and lower rates of venous thromboembolism (2.53% vs. 6.75%) (p < 0.001), severe heart failure (56.50% vs. 68.03%) (p < 0.001), and severe kidney diseases (1.38% vs. 3.59%) (p < 0.001), but there were more subjects with Alzheimer’s disease (7.49% vs. 4.31%) (p = 0.001). Individuals in the DOAC group had fewer prescriptions of furosemide (48.53% vs. 55.75%) (p < 0.001) and fibrates (2.32% vs. 3.88%) (p = 0.044). They also had more prescriptions of proton pump inhibitors (43.95% vs. 39.44%) (p = 0.006) and antirheumatics (1.60% vs. 0.65%) (p = 0.009) than those in the VKA group. There was no difference in mortality. This study revealed that prescribing practices for DOAC have changed over time. |
format | Online Article Text |
id | pubmed-9859400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98594002023-01-21 Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 Azzoug, Chana Nuémi, Gilles Menu, Didier De Maistre, Emmanuel Boulin, Mathieu Putot, Alain Manckoundia, Patrick Int J Environ Res Public Health Article Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit–risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a study in 2017, we observed that older adults did not seem to receive the same modalities of oral anticoagulants as younger individuals for various reasons. To assess anticoagulation prescribing practices over time, we repeated this cross-sectional study by comparing very old individuals taking DOAC to those taking VKA. Ambulatory individuals aged 80 years and older were included. They were affiliated with the Mutualité Sociale Agricole of Burgundy and were refunded for a medical prescription of oral anticoagulation in March 2021. The demographic characteristics, registered chronic diseases (RCD), number and types of prescribed drugs, and mortality of the DOAC group and the VKA group were compared. A total of 4275 subjects were included in the study: 67.44% (2883) received DOAC and 32.56% (1392) received VKA. The two groups were similar in age. In the DOAC group, there were more women (54.98% vs. 46.98%) (p < 0.001), fewer RCD (91.47% vs. 93.68%) (p = 0.014), and lower rates of venous thromboembolism (2.53% vs. 6.75%) (p < 0.001), severe heart failure (56.50% vs. 68.03%) (p < 0.001), and severe kidney diseases (1.38% vs. 3.59%) (p < 0.001), but there were more subjects with Alzheimer’s disease (7.49% vs. 4.31%) (p = 0.001). Individuals in the DOAC group had fewer prescriptions of furosemide (48.53% vs. 55.75%) (p < 0.001) and fibrates (2.32% vs. 3.88%) (p = 0.044). They also had more prescriptions of proton pump inhibitors (43.95% vs. 39.44%) (p = 0.006) and antirheumatics (1.60% vs. 0.65%) (p = 0.009) than those in the VKA group. There was no difference in mortality. This study revealed that prescribing practices for DOAC have changed over time. MDPI 2023-01-13 /pmc/articles/PMC9859400/ /pubmed/36674204 http://dx.doi.org/10.3390/ijerph20021448 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Azzoug, Chana Nuémi, Gilles Menu, Didier De Maistre, Emmanuel Boulin, Mathieu Putot, Alain Manckoundia, Patrick Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 |
title | Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 |
title_full | Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 |
title_fullStr | Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 |
title_full_unstemmed | Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 |
title_short | Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 |
title_sort | direct oral anticoagulants versus vitamin k antagonists in individuals aged 80 years and older: an overview in 2021 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859400/ https://www.ncbi.nlm.nih.gov/pubmed/36674204 http://dx.doi.org/10.3390/ijerph20021448 |
work_keys_str_mv | AT azzougchana directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021 AT nuemigilles directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021 AT menudidier directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021 AT demaistreemmanuel directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021 AT boulinmathieu directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021 AT putotalain directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021 AT manckoundiapatrick directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021 |